Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
Media Centre
>
Coverage
Overview
Video
Coverage
Coverage
17-Jun-2022
Kazia Therapeutics secures orphan drug designation for treatment of AT/RT tumours with paxalisib
14-Jun-2022
Stocks of the Hour: Kazia Therapeutics, Westgold Resources &Lake Resources
13-Jun-2022
Kazia Therapeutics welcomes presentation of positive paxalisib data at international symposium
8-Jun-2022
Kazia onto next chapter in Phase 2 brain metastases trial
7-Jun-2022
Kazia Therapeutics’ Phase 2 paxalisib study moves to expansion stage in breast cancer brain metastases cohort
31-May-2022
Kazia Therapeutics’ paxalisib now the subject of multi-drug platform study at the University Hospital, Zurich
11-May-2022
Sector Watch: Healthcare - M&Afever on the cards?
11-May-2022
Nasdaq jumps as Dow falls, Immutep, Antisense, Pushpay, AGL, Star on watch: ASX poised to open lower
5-May-2022
Kazia Therapeutics and its flagship asset have made significant progress against brain cancers: Pitt Street Research
2-May-2022
Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting
Previous
1
2
3
4
5
6
7
8
Next
